Lloyd Sanders will succeed Murali Prahalad as president and CEO of cancer diagnostic company Epic Sciences Inc. (San Diego, Calif.). Sanders was president of the oncology segment of molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN)....

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped 38% on Oct. 10 after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein (KLKB1) inhibitor, along with...

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped $2.79 (38%) to $10.17 on Tuesday after the company granted Merck & Co. Inc. (NYSE:MRK) options to acquire its most advanced program KVD001 , an intravitreal plasma kallikrein inhibitor (KLKB1),...

Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81% stake in the combined company. The combined company will focus on KalVista’s pipeline, which includes KVD001 , an intravitreal plasma...

KalVista Pharmaceuticals Ltd. , Salisbury, U.K.   Business: Ophthalmic   Date completed: 2015-07-22   Type: Venture financing   Raised: $33 million   Investors: Novo A/S ; SV Life Sciences ; RA Capital Management; Longwood Fund; Venrock...

KalVista Pharmaceuticals Ltd. (Salisbury, U.K.) raised $33 million in a series B round led by new investor RA Capital. New investors Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also...

KalVista began an open-label, U.S. Phase I trial to evaluate single ascending doses of intravitreal KVD001 in about 17 patients. KalVista Pharmaceuticals Ltd. , Southampton, U.K.   Product: KVD001   Business: Ophthalmic   Molecular target: NA...